Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8956145 | 0.94 | MAPT (0.47) | ATMTDP1MAPTRAPGEF3ALDH1A1 | |
| SCHEMBL2338671 | 0.92 | TDP1 (0.50) | ATMTDP1MAPTRAPGEF3ALDH1A1 | |
| SCHEMBL12210768 | 0.86 | MAPT (0.60) | ATMTDP1MAPTRAPGEF3ALDH1A1 | |
| SCHEMBL9275306 | 0.86 | MAPT (0.51) | MAPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL4014456 | 0.83 | MAPT (0.68) | ATMTDP1MAPTRAPGEF3ALDH1A1 | |
| SCHEMBL8778509 | 0.82 | MAPT (0.47) | ATMTDP1MAPTRAPGEF3ALDH1A1 | |
| SCHEMBL15923825 | 0.82 | MAPT (0.56) | ATMTDP1MAPTALDH1A1LMNA | |
| SCHEMBL20982641 | 0.82 | MAPT (0.71) | TDP1MAPTALDH1A1LMNAKDM4E | |
| SCHEMBL26086348 | 0.82 | MAPT (0.51) | ATMTDP1MAPTRAPGEF3ALDH1A1 | |
| SCHEMBL21460712 | 0.81 | SIRT5 (0.47) | ATMTDP1MAPTRAPGEF3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7642265-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642265-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ZC3HAV1, NXF1, ZC3HAV1L | ATM 4810/4885TDP1 1316/4885MAPT 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.